In pediatric lead poisoning, the presence of encephalopathy or a blood lead level above 70 µg/dL represents a high-severity threshold that requires immediate hospital admission and a more intensive treatment strategy than lower-exposure presentations.
This protocol applies to a child under 18 years of age who either presents with lead-related encephalopathy or has a blood lead level exceeding 70 µg/dL. Either criterion alone is sufficient to indicate the need for inpatient parenteral therapy.
Management at this severity threshold requires hospital admission and inpatient parenteral chelation. The regimen involves two parenteral chelating agents used in combination, administered over a defined multi-day course.
The complete sequence, individual agents, routes, dosing, and monitoring parameters are available in the full protocol — not shown here.
Children with blood lead levels between 45 and 70 µg/dL should undergo chelation, usually with oral succimer; those with encephalopathy or with blood lead levels in excess of 70 µg/dL should be admitted to the hospital for parenteral therapy with BAL and EDTA.
Therapy begins with BAL intramuscularly every 4 hours, establishment of adequate urinary output (hydration as needed), followed by CaNa2-EDTA continuous infusion.
CaNa2-EDTA may be administered intramuscularly in divided doses every 4 hours.
This combined therapy is continued for 5 days while liver and renal functions and blood lead levels are monitored.
Once initiated, chelation therapy should be continued until symptoms improve and acceptable blood lead levels are achieved.
View source ↗